- Economy
- Education And Career
- Companies & Markets
- Gadgets & Technology
- After Hours
- Healthcare
- Banking & Finance
- Entrepreneurship
- Energy & Infra
- Case Study
- Video
- More
- Sustainability
- Web Exclusive
- Opinion
- Luxury
- Legal
- Property Review
- Cloud
- Blockchain
- Workplace
- Collaboration
- Developer
- Digital India
- Infrastructure
- Work Life Balance
- Test category by sumit
- Sports
- National
- World
- Entertainment
- Lifestyle
- Science
- Health
- Tech
Latest Articles in ZyCoV D
Zydus Cadila's Coronavirus Vaccine ZyCoV-D To Be Used In 7 States Initially
ZyCov-D, which is the first COVID-19 vaccine to be cleared by India's drug regulator for those aged 12 years and above, will only be administered to adults in the seven states as of now, sources said.
Read More
SEC Recommendations On Covaxin's Approval For 2-18 Age Group Being Examined: Govt
The CDSCO has also approved COVID-19 vaccine (ZyCoV-D) of Cadila Healthcare for restricted use in emergency situations in the age group 12 years and above
Read More
Will Offer Free Jabs To Children With 'Specified Co-Morbidities': Apollo
Zydus Cadila's Covid vaccine ZyCoV-D has already received Emergency Use Authorisation from the Drugs Controller General of India (DCGI) in the country and will be administered to those aged 12 years and above.
Read More
Cadila Healthcare Gets DCGI Nod To Conduct Phase III Trials For Two-Dose COVID Vaccine
Shares of Cadila Healthcare Ltd were trading at Rs 563.95 per scrip on BSE, up 0.29 percent from their previous close
Read More
PM Modi Hails Approval Of World’s First DNA Based ‘ZyCov-D’ Vaccine
India is fighting COVID-19 with full vigour. The approval for the world's first DNA-based ‘ZyCov-D’ vaccine of Zydus Universe is a testimony to the innovative zeal of India’s scientists. A momentous feat indeed, said PM Modi
Read More
Zydus Cadila Gets DCGI Nod For Phase-3 Clinical Trials For Covid-19 Vaccine
The Ministry said that Zydus Cadila completed Phase-I/II clinical trials of this DNA Vaccine candidate, in India, in more than 1,000 participants and interim data indicated that the vaccine is safe and immunogenic when three doses were administered intradermally.
Read More